Leukemia, T-Cell, Chronic disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LKM005 MIFTS: 34	Leukemia, T-Cell, Chronic Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Leukemia, T-Cell, Chronic

MalaCards integrated aliases for Leukemia, T-Cell, Chronic:

Name: Leukemia, T-Cell, Chronic ¹⁹ ⁷⁵ ⁷¹

Chronic T-Cell Leukemia ¹⁹

Leukemia, T-Cell ⁷¹

T-Cell Leukemia ¹⁹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Bone diseases Immune diseases Blood diseases

See all MalaCards categories (disease lists)

External Ids:

UMLS ⁷¹ C0023492 C0023494

Sources

Summaries for Leukemia, T-Cell, Chronic

GARD: ¹⁹ A slow-growing type of leukemia (blood cancer) in which too many lymphocytes are found in the bone marrow and/or blood. The T-cell is specified as the defective cell line.

MalaCards based summary: Leukemia, T-Cell, Chronic, also known as chronic t-cell leukemia, is related to adult t-cell leukemia/lymphoma and t-cell acute lymphoblastic leukemia. The drugs Zidovudine and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone.

Wikipedia: ⁷⁵ T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and... more...

Sources

Related Diseases for Leukemia, T-Cell, Chronic

Diseases in the Leukemia, T-Cell, Chronic family:

Human T-Cell Leukemia Virus Type 1	Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3

Diseases related to Leukemia, T-Cell, Chronic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 672)

#	Related Disease	Score
1	adult t-cell leukemia/lymphoma	12.0
2	t-cell acute lymphoblastic leukemia	11.9
3	human t-cell leukemia virus type 1	11.8
4	tropical spastic paraparesis	11.6
5	human t-cell leukemia virus type 2	11.6
6	t-cell adult acute lymphocytic leukemia	11.5
7	t-cell prolymphocytic leukemia	11.5
8	n syndrome	11.5
9	leukemia	11.4
10	pediatric t-cell leukemia	11.4
11	human t-cell leukemia virus type 3	11.2
12	lymphoma	11.2
13	burkitt lymphoma	11.2
14	infective dermatitis associated with htlv-1	11.2
15	adult syndrome	11.1
16	spinal cord disease	11.1
17	hereditary spastic paraplegia	11.0
18	spastic paraparesis	11.0
19	leukemia, acute lymphoblastic	10.9
20	precursor t-cell acute lymphoblastic leukemia	10.8
21	lymphoma, hodgkin, classic	10.8
22	human immunodeficiency virus type 1	10.8
23	severe combined immunodeficiency	10.7
24	immune deficiency disease	10.7
25	lymphoproliferative syndrome	10.7
26	leukemia, chronic lymphocytic	10.7
27	acquired immunodeficiency syndrome	10.7
28	fungal infectious disease	10.7
29	mycosis fungoides	10.7
30	graft-versus-host disease	10.7
31	peripheral t-cell lymphoma	10.7
32	primary cutaneous t-cell non-hodgkin lymphoma	10.7
33	hematologic cancer	10.6
34	b-cell lymphoma	10.6
35	sezary's disease	10.6
36	viral infectious disease	10.6
37	strongyloidiasis	10.6
38	uveitis	10.5
39	hairy cell leukemia	10.5
40	primary agammaglobulinemia	10.5
41	lymphoma, non-hodgkin, familial	10.5
42	acute leukemia	10.5
43	splenomegaly	10.5
44	exanthem	10.5
45	chronic bilirubin encephalopathy	10.5
46	aplastic anemia	10.5
47	pneumocystosis	10.5
48	down syndrome	10.5
49	acute graft versus host disease	10.5
50	retinoblastoma	10.5

Graphical network of the top 20 diseases related to Leukemia, T-Cell, Chronic:

Sources

Symptoms & Phenotypes for Leukemia, T-Cell, Chronic

Sources

Drugs & Therapeutics for Leukemia, T-Cell, Chronic

Drugs for Leukemia, T-Cell, Chronic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Zidovudine

Approved

Phase 4

30516-87-1

35370

Peginterferon alfa-2b

Approved

Phase 4

215647-85-1, 99210-65-8

Valproic acid

Approved, Investigational

Phase 4

99-66-1

3121

Daclizumab

Investigational, Withdrawn

Phase 4

152923-56-3

Interferon alpha-2

Phase 4

interferons

Phase 4

Interferon-alpha

Phase 4

Reverse Transcriptase Inhibitors

Phase 4

Neurotransmitter Agents

Phase 4

Psychotropic Drugs

Phase 4

Anticonvulsants

Phase 4

Idarubicin

Approved

Phase 2, Phase 3

58957-92-9

42890

Decitabine

Approved, Investigational

Phase 3

2353-33-5

451668

Aclarubicin

Investigational

Phase 3

57576-44-0

Adjuvants, Immunologic

Phase 3

homoharringtonine

Phase 3

3628

Miconazole

Approved, Investigational, Vet_approved

Phase 1, Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 1, Phase 2

23593-75-1

2812

Etoposide

Approved

Phase 2

33419-42-0

36462

Triamcinolone

Approved, Vet_approved

Phase 1, Phase 2

124-94-7

31307

Alemtuzumab

Approved, Investigational

Phase 2

216503-57-0

Cladribine

Approved, Investigational

Phase 2

4291-63-8

20279

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Mogamulizumab

Approved, Investigational

Phase 2

1159266-37-1

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

4159 6741

Everolimus

Approved

Phase 1, Phase 2

159351-69-6

70789204 6442177

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Lamivudine

Approved, Investigational

Phase 2

134678-17-4

60825

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Sirolimus

Approved, Investigational

Phase 1, Phase 2

53123-88-9

5284616 6436030

Vindesine

Approved, Investigational

Phase 2

59917-39-4, 53643-48-4

40839

Iron

Approved

Phase 2

7439-89-6

29936

Deferasirox

Approved, Investigational

Phase 2

201530-41-8

214348 5493381

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 1, Phase 2

62-33-9, 60-00-4

6049

Pentetic acid

Approved

Phase 1, Phase 2

67-43-6

Azacitidine

Approved, Investigational

Phase 2

320-67-2

9444

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Lomustine

Approved, Investigational

Phase 2

13010-47-4

3950

Irinotecan

Approved, Investigational

Phase 2

97682-44-5, 100286-90-6

60838

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Venetoclax

Approved, Investigational

Phase 2

1257044-40-8

49846579

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Interventional clinical trials:

(show top 50) (show all 152)

#	Name	Status	NCT ID	Phase	Drugs
1	HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens	Completed	NCT03226119	Phase 4
2	HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)	Completed	NCT01418430	Phase 4	CHOP-daclizumab
3	Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b	Terminated	NCT00854581	Phase 4	Valproic Acid;Zidovudine
4	An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma	Unknown status	NCT03553238	Phase 2, Phase 3	Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
5	An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia	Unknown status	NCT03564704	Phase 2, Phase 3	Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
6	Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.	Completed	NCT00145002	Phase 3	VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
7	A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients	Recruiting	NCT04446130	Phase 3	Decitabine combined with HAAG Regimen
8	Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia	Unknown status	NCT03613428	Phase 1, Phase 2	Ruxolitinib;Vincristine;Prednisone
9	A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use	Completed	NCT00095381	Phase 2	forodesine hydrochloride (BCX-1777)
10	German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure	Completed	NCT00199030	Phase 2	Alemtuzumab (MabCampath);Cladribine
11	Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies	Completed	NCT01839916	Phase 2
12	A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens	Completed	NCT00489203	Phase 2	beclomethasone dipropionate;placebo;tacrolimus;methotrexate
13	Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma	Completed	NCT02631746	Phase 2
14	Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma	Completed	NCT00081874	Phase 1, Phase 2	RAD001
15	Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial	Completed	NCT00078858	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
16	A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)	Completed	NCT01110135	Phase 2	bendamustine hydrochloride;dexamethasone;etoposide
17	A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil	Completed	NCT00089011	Phase 2	fludarabine phosphate;mycophenolate mofetil;tacrolimus
18	Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil	Completed	NCT00006251	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
19	Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	Completed	NCT01626664	Phase 2	Pralatrexate;gemcitabine plus oxaliplatin;DHAP
20	Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia	Completed	NCT00061048	Phase 2
21	Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation	Completed	NCT00049504	Phase 2	cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
22	Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma	Completed	NCT00041327	Phase 2	Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
23	A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma	Completed	NCT00006473	Phase 2	oxaliplatin
24	A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma	Completed	NCT00131937	Phase 2	sorafenib tosylate
25	A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL)	Completed	NCT00005080	Phase 2	nelarabine
26	A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia	Completed	NCT00001941	Phase 1, Phase 2
27	A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma	Completed	NCT00918333	Phase 1, Phase 2	panobinostat;everolimus
28	A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma	Completed	NCT00611208	Phase 2
29	Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial	Completed	NCT00040846	Phase 2	fludarabine phosphate;mycophenolate mofetil;cyclosporine
30	Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma	Completed	NCT00920790	Phase 2
31	A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy	Completed	NCT01075321	Phase 1, Phase 2	everolimus;lenalidomide
32	Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial	Completed	NCT00118352	Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
33	Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma	Completed	NCT00082888	Phase 2	Tipifarnib
34	A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies	Completed	NCT00072514	Phase 2	gemcitabine hydrochloride;carboplatin;dexamethasone
35	Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma	Completed	NCT01000285	Phase 1, Phase 2	Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
36	Phase II Study of MK-2206 in Patients With Relapsed Lymphoma	Completed	NCT01258998	Phase 2	Akt inhibitor MK2206
37	A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Completed	NCT01261247	Phase 2	panobinostat
38	Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma	Completed	NCT01378871	Phase 2	IMTOX-25
39	A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma	Completed	NCT01274533	Phase 2	Lenalidomide
40	Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease)	Completed	NCT01173887	Phase 2	VCAP/AMP/VECP(mLSG15)
41	A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation	Completed	NCT01529827	Phase 2	fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
42	High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma	Completed	NCT01177371	Phase 2	busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
43	Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL)	Completed	NCT01712659	Phase 1, Phase 2	Ruxolitinib;ruxolitinib
44	Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma	Completed	NCT01466881	Phase 2	Alisertib
45	A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation	Completed	NCT01427881	Phase 2	cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
46	A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma	Completed	NCT01724177	Phase 2	Lenalidomide
47	A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors	Completed	NCT01326702	Phase 1, Phase 2	Bendamustine Hydrochloride;Veliparib
48	Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload	Completed	NCT01273766	Phase 2	deferasirox
49	PHASE I/II STUDY OF TAC-EXPRESSING ADULT T-CELL LEUKEMIA (ATL) WITH YTTRIUM-90 (90Y)-RADIOLABELED HUMANIZED ANTI-TAC AND CALCIUM-DTPA	Completed	NCT00019227	Phase 1, Phase 2	pentetic acid calcium
50	A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma	Recruiting	NCT02737046	Phase 2	Belinostat;Zidovudine;Interferon-Alfa-2b;Pegylated Interferon-Alfa-2b

Search NIH Clinical Center for Leukemia, T-Cell, Chronic

Sources

Genetic Tests for Leukemia, T-Cell, Chronic

Sources

Anatomical Context for Leukemia, T-Cell, Chronic

Organs/tissues related to Leukemia, T-Cell, Chronic:

MalaCards : Bone Marrow, T Cells, Bone, Liver, Spleen, Skin, Myeloid

Sources

Publications for Leukemia, T-Cell, Chronic

Articles related to Leukemia, T-Cell, Chronic:

(show top 50) (show all 9261)

#	Title	Authors	PMID	Year
1	ANK Therapeutic Prospects and Usefulness of PD-L1 and NK Activity as Biomarkers for Predicting Treatment Efficacy Revealed from the Treatment Course of Patients with HTLV-1-Associated Bronchioloalveolar Disease. ⁶²	Nagai K...Teshigawara K	36282976	2023
2	Discovery of Aptamers Against Cell Surface Markers Using Ligand-Guided Selection. ⁶²	Williams N...Mallikaratchy P	36156771	2023
3	Genome-wide methylation analysis of pre-pregnancy women in hypothyroidism. ⁶²	Cai W...Hu X	33455507	2022
4	Increasing horizontal transmission of human T-cell leukemia virus type 1 in adolescents and young adults in Japan. ⁶²	Sagara Y...Hamaguchi I	36370501	2022
5	Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma. ⁶²	Madugula KK...Jain P	35615924	2022
6	Molecular insight into the study of adult T-cell leukemia/lymphoma (ATLL): Ten-year studies on HTLV-1 associated diseases in an endemic region. ⁶²	Ashrafi F...Abdolrahim Rezaee S	36108787	2022
7	Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. ⁶²	Hsu A...Carneiro BA	35815408	2022
8	Prognostic role of controlling nutritional status score in hematological malignancies. ⁶²	Zhang Y...Yu L	35622088	2022
9	Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. ⁶²	Hu Y...Huang H	36151216	2022
10	HTLV-I associated bronchioloalveolar disorder (HABA): disease concept and differential diagnosis of an unsolved disease entity. ⁶²	Ohmoto A...Katsura K	36437745	2022
11	Investigation of berberine and its derivatives in Sars Cov-2 main protease structure by molecular docking, PROTOX-II and ADMET methods: in machine learning and in silico study. ⁶²	Oner E...Choowongkomon K	36369803	2022
12	Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation. ⁶²	Haji S...Ogawa Y	36436130	2022
13	CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma. ⁶²	Kameda T...Shimoda K	36446869	2022
14	Cholesterol metabolism and lipid droplet vacuoles; a potential target for the therapy of aggressive lymphoma. ⁶²	Yano H...Komohara Y	36436934	2022
15	A frequent PLCγ1 mutation in adult T-cell leukemia/lymphoma determines functional properties of the malignant cells. ⁶²	Prawiro C...Bangham CRM	36442790	2022
16	Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma. ⁶²	Hiramatsu H...Ishida T	36420800	2022
17	Radiation Recall Dermatitis after Donor Lymphocyte Infusion for Adult T cell Leukemia Lymphoma post Allogeneic Stem Cell Transplant. ⁶²	Hardy-Abeloos C...Shaikh F	36347452	2022
18	Circulating clover-leaf cells presenting in acute-type adult T-cell leukemia-lymphoma. ⁶²	Lin YW...Lee MY	36467847	2022
19	Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation. ⁶²	Fuji S...Ishikawa J	35734929	2022
20	A therapeutically targetable NOTCH1-SIRT1-KAT7 axis in T-cell Leukemia. ⁶²	Lancho O...Herranz D	36322781	2022
21	Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. ⁶²	Chiba M...Nakagawa M	35921533	2022
22	Ancestral APOBEC3B Nuclear Localization Is Maintained in Humans and Apes and Altered in Most Other Old World Primate Species. ⁶²	Auerbach AA...Harris RS	36374108	2022
23	Identification of the OA-related metabolism-related genes, corresponding transcription factors, relevant pathways, and specific bioactive small molecules. ⁶²	Cao F...Xu J	36152536	2022
24	Rab11-FIP1C Is Dispensable for HIV-1 Replication in Primary CD4+ T Cells, but Its Role Is Cell Type Dependent in Immortalized Human T-Cell Lines. ⁶²	Fernandez-de Cespedes MV...Freed EO	36354340	2022
25	Potential Anti-Tumor Activity of Nardoguaianone L Isolated from Nardostachys jatamansi DC. in SW1990 Cells. ⁶²	Sang CY...Yang JL	36364317	2022
26	Identification of differentially expressed genes and pathways in diquat and paraquat poisoning using bioinformatics analysis. ⁶²	Miao C...Fan D	35392760	2022
27	Establishment of a Cynomolgus Macaque Model of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Direct Inoculation of Adult T-Cell Leukemia Patient-Derived Cell Lines for HTLV-1 Infection. ⁶²	Urano E...Yasutomi Y	36314828	2022
28	Acute type adult T-cell leukemia cells proliferate in the lymph nodes rather than in peripheral blood. ⁶²	Mizuguchi M...Tanaka Y	35459881	2022
29	Majocchi Granuloma in a Patient with Adult T-cell Leukemia. ⁶²	Ishibashi T...Fukushima S	36409384	2022
30	Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarker. ⁶²	Johansson P...Bergmann AK	36376973	2022
31	VEGF Polymorphism rs3025039 and Human T-Cell Leukemia Virus 1 (HTLV-1) Infection among Older Japanese Individuals: A Cross-Sectional Study. ⁶²	Shimizu Y...Maeda T	36290496	2022
32	HTLV infection in Brazil's second-largest indigenous reserve. ⁶²	Amianti C...Motta-Castro ARC	36202887	2022
33	Live attenuated VZV vaccination induces antitumor immunity in ATLL patients. ⁶²	Jo T...Shigematsu K	36181532	2022
34	Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study. ⁶²	Imaizumi Y...Tsukasaki K	36308678	2022
35	Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma. ⁶²	Yanagida E...Ohshima K	35122292	2022
36	Primary Effusion Lymphoma-like ATL Developing During Hemodialysis. ⁶²	Masaki M...Masaki Y	36261387	2022
37	Diagnosis and Early Prediction of Lymphoma Using High-Throughput Clonality Analysis of Bovine Leukemia Virus-Infected Cells. ⁶²	Okagawa T...Ohashi K	36227090	2022
38	Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell lines despite NOTCH1 expression. ⁶²	Suzuki S...Ishitsuka K	36243685	2022
39	Identification of potential crucial genes and key pathways shared in Inflammatory Bowel Disease and cervical cancer by machine learning and integrated bioinformatics. ⁶²	Nguyen TB...Nguyen-Thanh T	36049413	2022
40	Various types of electrochemical biosensors for leukemia detection and therapeutic approaches. ⁶²	Chupradit S...Bidares R	35588855	2022
41	Regulation of Retroviral and SARS-CoV-2 Protease Dimerization and Activity through Reversible Oxidation. ⁶²	Davis DA...Yarchoan R	36290777	2022
42	The importance of the clinical classification of adult T-cell leukemia/lymphoma (ATLL) in the prognosis. ⁶²	Oliveira PD...Bittencourt AL	36260617	2022
43	[Clinical Study of Chemotherapy Combined with Antivirals for Adult T-cell Leukemia/Lymphoma]. ⁶²	Lin Y...Chen Q	36208242	2022
44	ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent. ⁶²	Luchtel RA...Maqbool SB	35675522	2022
45	Particularities of Neurological Manifestations in Adult T-Cell Leukemia/Lymphoma: Need for a Multidisciplinary Approach-A Narrative Review. ⁶²	Iordan I...Bumbea H	36363509	2022
46	TCL-150 Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. ⁶²	Narvel H...Sica RA	36164124	2022
47	Signaling factors potentially associated to the pathogenesis of Adult T-cell leukemia /lymphoma: A network-analysis and novel findings assessment. ⁶²	Mozhgani SH...Rezaee SA	35868352	2022
48	Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. ⁶²	Dou F...Gao J	36310058	2022
49	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. ⁶²	Tanaka N...Ishida T	35417939	2022
50	The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development. ⁶²	Tornesello ML...Buonaguro FM	36358677	2022